Corporate VC Funds Drive Innovation For Aileron’s Novel Stapled Peptide Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Aileron’s stapled peptides spark investment interest from four big pharma VC arms.
You may also be interested in...
Aileron Raises $30M From Existing Investors To Advance Pair Of Stapled Peptide Candidates
The Cambridge, Mass., biotech plans to bring a candidate for cancer into clinical development next year, while starting Phase Ib dose-finding research with its endocrinology disorder candidate.
Roche Partners With Peptide Specialist Aileron For Five Targets
A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.
Roche Partners With Peptide Specialist Aileron For Five Targets
A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.